OPERA-01: Palazestrant vs. Standard-of-Care for ER+/HER2- MBC

Elisabeth de Kermadec will discuss the OPERA-01 phase 3 study, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance. We will discuss her study and review the poster “the OPERA-01 phase 3 study with us, focusing on the efficacy of palazestrant (OP-1250) compared to standard treatments in ER+, HER2- metastatic breast cancer post endocrine therapy and CDK4/6 inhibitor resistance.” which was presented at the 2024 American Society of Clinical Oncology Annual Meeting (ASCO).

 

Date

Aug 22 2024

Time

ET
10:00 am - 11:00 am

Zoom Webinar

Category
REGISTER

Speaker